Gene editing firm Tome Biosciences has acquired startup Replace Therapeutics less than a month after Tome emerged from stealth with $213M in funding. This development adds fuel to an already hot field.In early December, Vertex and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel [exa-cel]) for sickle cell became the first ever FDA-approved CRISPR/Cas9 genome-edited cell therapy. Axios […]